D.E. Shaw & Co’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-396,076
| Closed | -$875K | – | 4611 |
|
|
2023
Q2 | $875K | Buy |
396,076
+42,577
| +12% | +$88.3K | ﹤0.01% | 3165 |
|
|
2023
Q1 | $898K | Sell |
353,499
-39,197
| -10% | -$77.5K | ﹤0.01% | 3238 |
|
|
2022
Q4 | $734K | Buy |
392,696
+83,132
| +27% | +$207K | ﹤0.01% | 3641 |
|
|
2022
Q3 | $795K | Buy |
309,564
+191,355
| +162% | +$476K | ﹤0.01% | 3749 |
|
|
2022
Q2 | $228K | Buy |
118,209
+41,278
| +54% | +$90.1K | ﹤0.01% | 4491 |
|
|
2022
Q1 | $228K | Buy |
76,931
+48,518
| +171% | +$183K | ﹤0.01% | 4791 |
|
|
2021
Q4 | $128K | Sell |
28,413
-27,094
| -49% | -$129K | ﹤0.01% | 5007 |
|
|
2021
Q3 | $270K | Sell |
55,507
-51,401
| -48% | -$283K | ﹤0.01% | 4418 |
|
|
2021
Q2 | $729K | Sell |
106,908
-109,745
| -51% | -$887K | ﹤0.01% | 3799 |
|
|
2021
Q1 | $1.53M | Sell |
216,653
-179,008
| -45% | -$1.29M | ﹤0.01% | 2804 |
|
|
2020
Q4 | $2.48M | Sell |
395,661
-218,893
| -36% | -$1.29M | ﹤0.01% | 2418 |
|
|
2020
Q3 | $3.33M | Sell |
614,554
-403,911
| -40% | -$2M | ﹤0.01% | 1995 |
|
|
2020
Q2 | $5.32M | Buy |
1,018,465
+457,341
| +82% | +$2.03M | 0.01% | 1629 |
|
|
2020
Q1 | $1.77M | Buy |
561,124
+301,041
| +116% | +$1.11M | ﹤0.01% | 2266 |
|
|
2019
Q4 | $1.05M | Buy |
260,083
+242,063
| +1,343% | +$840K | ﹤0.01% | 2949 |
|
|
2019
Q3 | $78K | Buy |
+18,020
| New | +$72.1K | ﹤0.01% | 3710 |
|
|
2018
Q1 | – | Sell |
-20,071
| Closed | -$359K | – | 3852 |
|
|
2017
Q4 | $359K | Buy |
+20,071
| New | +$419K | ﹤0.01% | 3156 |
|
|
2017
Q1 | – | Sell |
-10,806
| Closed | -$166K | – | 3668 |
|
|
2016
Q4 | $166K | Sell |
10,806
-10,650
| -50% | -$138K | ﹤0.01% | 3293 |
|
|
2016
Q3 | $279K | Buy |
+21,456
| New | +$284K | ﹤0.01% | 3080 |
|
|
2015
Q1 | – | Sell |
-98,315
| Closed | -$3.79M | – | 4104 |
|
|
2014
Q4 | $3.79M | Buy |
98,315
+97,032
| +7,563% | +$2.32M | ﹤0.01% | 1774 |
|
|
2014
Q3 | $31K | Sell |
1,283
-3,693
| -74% | -$96.4K | ﹤0.01% | 4033 |
|
|
2014
Q2 | $119K | Buy |
4,976
+629
| +14% | +$20.5K | ﹤0.01% | 4070 |
|
|
2014
Q1 | $161K | Buy |
4,347
+50
| +1% | +$1.98K | ﹤0.01% | 4127 |
|
|
2013
Q4 | $173K | Buy |
4,297
+1,243
| +41% | +$52.8K | ﹤0.01% | 4297 |
|
|
2013
Q3 | $117K | Buy |
3,054
+614
| +25% | +$22K | ﹤0.01% | 4176 |
|
|
2013
Q2 | $88K | Buy |
+2,440
| New | +$105K | ﹤0.01% | 3883 |
|
D.E. Shaw & Co's PRTK Position: Q3 2023 in Review
D.E. Shaw & Co sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 396,076 shares — an estimated $875K sold.
D.E. Shaw & Co first reported a position in PRTK in Q2 2013 and held it in 26 quarters. The position peaked at $5.32M in Q2 2020. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- D.E. Shaw & Co reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- D.E. Shaw & Co sold 396,076 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $875K.
- D.E. Shaw & Co first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 26 quarters.
- D.E. Shaw & Co's Paratek Pharmaceuticals, Inc. position peaked at $5.32M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.